Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive myeloid neoplasm which shows a high rate of central nervous system (CNS) recurrence and overall survival (OS) of <1 year. Despite this, screening for CNS involvement is not routinely performed at diagnosis and intrathecal (IT) prophylaxis is not regularly administered in BPDCN. Here, we prospectively evaluated 13 consecutive BPDCN patients for the presence of CNS involvement by flow cytometry. Despite none of the patients presented with neurological symptoms, occult CNS involvement was detected in 6/10 cases evaluated at diagnosis and 3/3 studied at relapse/progression. BPDCN patients evaluated at diagnosis received IT treatment -either CNS prophylaxis (n = 4) or active therapy (n = 6)- and all but one remain alive (median follow-up of 20 months). In contrast, all three patients assessed at relapse/progression died. The potential benefit of IT treatment administered early at diagnosis on OS and CNS recurrence-free survival of BPDCN was further confirmed in a retrospective cohort of another 23 BPDCN patients. Our results show that BPDCN patients studied at diagnosis frequently display occult CNS involvement; moreover, they also indicate that treatment of occult CNS disease might lead to a dramatically improved outcome of BPDCN.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Oncotarget - 7(2016), 9 vom: 01. März, Seite 10174-81 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Martín-Martín, Lourdes [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ALL therapy |
|---|
| Anmerkungen: |
Date Completed 30.12.2016 Date Revised 13.11.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.18632/oncotarget.7101 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM257121862 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM257121862 | ||
| 003 | DE-627 | ||
| 005 | 20231224182129.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/oncotarget.7101 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0857.xml |
| 035 | |a (DE-627)NLM257121862 | ||
| 035 | |a (NLM)26840087 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Martín-Martín, Lourdes |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.12.2016 | ||
| 500 | |a Date Revised 13.11.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive myeloid neoplasm which shows a high rate of central nervous system (CNS) recurrence and overall survival (OS) of <1 year. Despite this, screening for CNS involvement is not routinely performed at diagnosis and intrathecal (IT) prophylaxis is not regularly administered in BPDCN. Here, we prospectively evaluated 13 consecutive BPDCN patients for the presence of CNS involvement by flow cytometry. Despite none of the patients presented with neurological symptoms, occult CNS involvement was detected in 6/10 cases evaluated at diagnosis and 3/3 studied at relapse/progression. BPDCN patients evaluated at diagnosis received IT treatment -either CNS prophylaxis (n = 4) or active therapy (n = 6)- and all but one remain alive (median follow-up of 20 months). In contrast, all three patients assessed at relapse/progression died. The potential benefit of IT treatment administered early at diagnosis on OS and CNS recurrence-free survival of BPDCN was further confirmed in a retrospective cohort of another 23 BPDCN patients. Our results show that BPDCN patients studied at diagnosis frequently display occult CNS involvement; moreover, they also indicate that treatment of occult CNS disease might lead to a dramatically improved outcome of BPDCN | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ALL therapy | |
| 650 | 4 | |a blastic plasmacytoid dendritic cell neoplasm | |
| 650 | 4 | |a central nervous system | |
| 650 | 4 | |a flow cytometry | |
| 650 | 4 | |a intrathecal prophylaxis | |
| 700 | 1 | |a Almeida, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Pomares, Helena |e verfasserin |4 aut | |
| 700 | 1 | |a González-Barca, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Bravo, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Giménez, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Heras, Cecilia |e verfasserin |4 aut | |
| 700 | 1 | |a Queizán, José-Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Ceballos, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez, Violeta |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Calvo, Carlota |e verfasserin |4 aut | |
| 700 | 1 | |a Álvarez, Rodolfo |e verfasserin |4 aut | |
| 700 | 1 | |a Caballero, María Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Orfao, Alberto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncotarget |d 2010 |g 7(2016), 9 vom: 01. März, Seite 10174-81 |w (DE-627)NLM199620113 |x 1949-2553 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2016 |g number:9 |g day:01 |g month:03 |g pages:10174-81 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/oncotarget.7101 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2016 |e 9 |b 01 |c 03 |h 10174-81 | ||